Evidence map›Paper›PMID 32121038›Full record

ArticleJournal of clinical medicine2020

Markov State Modelling of Disease Courses and Mortality Risks of Patients with Community-Acquired Pneumonia.

Jens Przybilla, Peter Ahnert, Holger Bogatsch, Frank Bloos, Frank M Brunkhorst, SepNet Critical Care Trials Group, Progress Study Group, Michael Bauer, Markus Loeffler, Martin Witzenrath and 2 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jens PrzybillaInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig, Germany.
Peter AhnertInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig, Germany.ORCID 0000-0002-1771-0856
Holger BogatschInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig, Germany.
Frank BloosDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
Frank M BrunkhorstDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
SepNet Critical Care Trials GroupSepNet Critical Care Trials Group c/o Sepsis-Stiftung, Carl-Zeiß-Str. 12, 07743 Jena, Germany.
Progress Study GroupDepartment of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Michael BauerDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
Markus LoefflerInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig, Germany.
Martin WitzenrathGerman Center for Lung Research (DZL), Aulweg 130, 35392 Gießen, Germany.ORCID 0000-0002-9787-5633
Norbert SuttorpGerman Center for Lung Research (DZL), Aulweg 130, 35392 Gießen, Germany.
Markus ScholzInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), Universität Leipzig, Härtelstr. 16-18, 04107 Leipzig, Germany.ORCID 0000-0002-4059-1779

Funding

Bundesministerium für Bildung und Forschung 01EO1002Bundesministerium für Bildung und Forschung 01KI0106Bundesministerium für Bildung und Forschung 01KI07113Bundesministerium für Bildung und Forschung 01KI1010IBundesministerium für Bildung und Forschung 01ZX1304ABundesministerium für Bildung und Forschung 01ZX1304BBundesministerium für Bildung und Forschung 01ZX1604BDeutsches Zentrum für Lungenforschung 82DZLJ19A1Deutsches Zentrum für Lungenforschung 82DZLJ19A2Thüringer Ministerium für Bildung, Wissenschaft und Kultur PE108-2
6 · The paper itself

Abstract

Community-acquired pneumonia (CAP) is one of the most frequent infectious diseases worldwide, with high lethality. Risk evaluation is well established at hospital admission, and re-evaluation is advised for patients at higher risk. However, severe disease courses may develop from all levels of severity. We propose a stochastic continuous-time Markov model describing daily development of time courses of CAP severity. Disease states were defined based on the Sequential Organ Failure Assessment (SOFA) score. Model calibration was based on longitudinal data from 2838 patients with a primary diagnosis of CAP from four clinical studies (PROGRESS, MAXSEP, SISPCT, VISEP). We categorized CAP severity into five disease states and estimated transition probabilities for CAP progression between these states and corresponding sojourn times. Good agreement between model predictions and clinical data was observed. Time courses of mortality were correctly predicted for up to 28 days, including validation with patient data not used for model calibration. We conclude that CAP disease course follows a Markov process, suggesting the necessity of daily monitoring and re-evaluation of patient's risk. Our model can be used for regular updates of risk assessments of patients and could improve the design of clinical trials by estimating transition rates for different risk groups.

Indexed as

community-acquired pneumoniacontinuous-time Markov modelmedical decision makingprognosissepsisSOFA scorestochastic model

Identifiers

PMID32121038
PMCPMC7074475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.